Effectiveness of Four Different Interventions Against Schistosoma haematobium in a Seasonal Transmission Setting of Côte d'Ivoire: A Cluster Randomized Trial.
Schistosoma haematobium
Côte d’Ivoire
interruption of transmission
schistosomiasis
seasonal transmission
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
received:
12
05
2021
pubmed:
15
9
2021
medline:
9
7
2022
entrez:
14
9
2021
Statut:
ppublish
Résumé
Annual mass drug administration (MDA) using praziquantel is the cornerstone of schistosomiasis morbidity control but is not sufficient to interrupt transmission. We implemented a cluster-randomized trial to compare the effectiveness of 4 different intervention packages to interrupt transmission of Schistosoma haematobium in a seasonal transmission setting of Côte d'Ivoire. Sixty-four localities with a S. haematobium prevalence in school children aged 13-14 years above 4% were randomly assigned to 1 of 4 intervention arms over a 3-year period: (1) the current standard strategy consisting of annual MDA before peak of transmission, (2) annual MDA after peak of transmission, (3) biannual MDA, and (4) standard MDA combined with snail control. The primary outcome was prevalence and intensity of S. haematobium infection in children aged 9-12 years 1 year after the final intervention, using urine filtration performed by experienced microscopists. By study end, we observed the lowest S. haematobium prevalence in the biannual MDA, compared to the standard treatment arm (0.6% vs 7.5%; odds ratio [OR] = 0.07, 95% confidence interval [CI] = .02 to .24). The prevalence in arms 2 and 4 was about 3.5%, which was not statistically significantly different from the standard strategy (both ORs 0.4, 95% CI = .1 to ~1.8). New cases of infection were still observed in all arms at study end. Biannual MDA was the only regimen that outperformed the standard treatment. All strategies resulted in decreased prevalence of infection; however, none of them was able to interrupt transmission of S. haematobium within a 3-year period. ISRCTN10926858.
Sections du résumé
BACKGROUND
Annual mass drug administration (MDA) using praziquantel is the cornerstone of schistosomiasis morbidity control but is not sufficient to interrupt transmission. We implemented a cluster-randomized trial to compare the effectiveness of 4 different intervention packages to interrupt transmission of Schistosoma haematobium in a seasonal transmission setting of Côte d'Ivoire.
METHODS
Sixty-four localities with a S. haematobium prevalence in school children aged 13-14 years above 4% were randomly assigned to 1 of 4 intervention arms over a 3-year period: (1) the current standard strategy consisting of annual MDA before peak of transmission, (2) annual MDA after peak of transmission, (3) biannual MDA, and (4) standard MDA combined with snail control. The primary outcome was prevalence and intensity of S. haematobium infection in children aged 9-12 years 1 year after the final intervention, using urine filtration performed by experienced microscopists.
RESULTS
By study end, we observed the lowest S. haematobium prevalence in the biannual MDA, compared to the standard treatment arm (0.6% vs 7.5%; odds ratio [OR] = 0.07, 95% confidence interval [CI] = .02 to .24). The prevalence in arms 2 and 4 was about 3.5%, which was not statistically significantly different from the standard strategy (both ORs 0.4, 95% CI = .1 to ~1.8). New cases of infection were still observed in all arms at study end.
CONCLUSIONS
Biannual MDA was the only regimen that outperformed the standard treatment. All strategies resulted in decreased prevalence of infection; however, none of them was able to interrupt transmission of S. haematobium within a 3-year period.
CLINICAL TRIALS REGISTRATION
ISRCTN10926858.
Identifiants
pubmed: 34519344
pii: 6369964
doi: 10.1093/cid/ciab787
pmc: PMC9258925
doi:
Substances chimiques
Praziquantel
6490C9U457
Banques de données
ISRCTN
['ISRCTN10926858']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2181-2190Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Parasit Vectors. 2015 Nov 10;8:584
pubmed: 26554822
Infect Dis Poverty. 2017 Mar 22;6(1):63
pubmed: 28327187
Trop Med Health. 2014 Jun;42(2 Suppl):25-32
pubmed: 25425948
J Infect Dis. 2017 Dec 12;216(11):1425-1433
pubmed: 28968877
N Engl J Med. 2009 Jan 8;360(2):106-9
pubmed: 19129524
PLoS Negl Trop Dis. 2011 Jun;5(6):e1194
pubmed: 21695107
Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):14-23
pubmed: 32400356
World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover
pubmed: 12592987
Lancet Glob Health. 2019 Aug;7(8):e1118-e1129
pubmed: 31255591
Am J Trop Med Hyg. 2020 Jul;103(1_Suppl):58-65
pubmed: 32400354
PLoS Negl Trop Dis. 2016 Jul 21;10(7):e0004794
pubmed: 27441556
Lancet. 2014 Jun 28;383(9936):2253-64
pubmed: 24698483
Trop Med Health. 2011 Mar;39(1 Suppl 1):3-44
pubmed: 22028594
Trop Med Infect Dis. 2021 Jan 08;6(1):
pubmed: 33429843
Parasit Vectors. 2015 Oct 22;8:553
pubmed: 26489831
PLoS Negl Trop Dis. 2021 Jan 15;15(1):e0008845
pubmed: 33449924
Lancet Infect Dis. 2020 Jul;20(7):e165-e172
pubmed: 32595046
PLoS Negl Trop Dis. 2015 Dec 28;9(12):e0004290
pubmed: 26709922
Parasit Vectors. 2017 Jul 26;10(1):353
pubmed: 28747222
PLoS Negl Trop Dis. 2014 Jun 05;8(6):e2913
pubmed: 24901333
Lancet Infect Dis. 2017 Feb;17(2):e64-e69
pubmed: 27914852
BMC Public Health. 2018 Jan 29;18(1):186
pubmed: 29378542
J Infect Dis. 2022 Mar 15;225(6):1050-1061
pubmed: 33263735
BMC Infect Dis. 2016 May 26;16:229
pubmed: 27230666
Am J Trop Med Hyg. 2017 Dec;97(6):1810-1817
pubmed: 29016344
Wkly Epidemiol Rec. 2014 Jan 10;89(2):21-8
pubmed: 24446558